Chemotherapy for Advanced Bladder Cancer: A Critical Review
Author Information
Author(s): D. Raghavan
Primary Institution: Royal Prince Alfred Hospital
Conclusion
Chemotherapy regimens for advanced bladder cancer show high response rates but do not consistently translate into improved survival.
Supporting Evidence
- Approximately 50% of patients with invasive transitional cell carcinoma will die within 5 years.
- Objective response rates of 20-35% can be achieved with certain chemotherapy drugs.
- Combination chemotherapy regimens have not shown a statistically significant survival benefit compared to single-agent therapies.
Takeaway
Doctors are trying different medicines to help people with bladder cancer, but just because some people get better doesn't mean everyone will live longer.
Methodology
The article reviews various chemotherapy regimens and their outcomes based on clinical trials.
Potential Biases
There is a risk of publication bias favoring positive results in the literature.
Limitations
The studies reviewed often lacked adequate patient accrual and did not consistently measure survival benefits.
Participant Demographics
The studies primarily involved elderly patients with invasive bladder cancer.
Statistical Information
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website